H2 receptor blockers efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Efficacy of H2 Receptor Blockers in Acid-Related Disorders
H2 receptor blockers (also known as H2 receptor antagonists or H2RAs) are effective in reducing gastric acid secretion and are widely used for treating conditions such as peptic ulcer disease, gastroesophageal reflux disease (GERD), and for the prevention of stress ulcers in critically ill patients . They work by selectively blocking histamine receptors on stomach parietal cells, leading to a decrease in both the volume and acidity of gastric juice . H2RAs are approved for short-term use in uncomplicated GERD, peptic or duodenal ulcers, and mild heartburn, and are sometimes used off-label for preventing stress ulcers, esophagitis, gastritis, and gastrointestinal bleeding Belovol2019Musukaeva2023.
In critically ill patients, H2RAs have shown comparable effectiveness to β-blockers in reducing all-cause mortality, and when used together, they may have an additive or synergistic effect on survival in patients with heart failure . In cardiac surgery patients, H2RAs were as effective as proton pump inhibitors (PPIs) for stress ulcer prophylaxis, with no significant differences in mortality, gastrointestinal bleeding, or other major outcomes .
Safety Profile and Adverse Effects of H2 Receptor Blockers
General Safety and Tolerability
H2 receptor blockers are generally considered safe and well-tolerated, with large post-marketing studies confirming their favorable safety profile Hinrichsen1992Belovol2019. They are available over the counter in many countries due to their established safety record .
Risks and Adverse Outcomes
However, recent comprehensive reviews and large-scale studies have identified some important safety concerns. H2RAs have been associated with an increased risk of certain adverse outcomes, including pneumonia, peritonitis, necrotizing enterocolitis, Clostridium difficile infection, liver cancer, gastric cancer, and hip fractures . Notably, no associations were found between H2RA use and risks for colorectal cancer, melanoma, kidney cancer, lung cancer, or common reproductive, renal, neurological, or cardiovascular diseases .
In very low birth weight (VLBW) infants, H2RA use was linked to a higher risk of death, necrotizing enterocolitis, or sepsis, leading to a decline in their use in neonatal intensive care units . This highlights the need for caution when prescribing H2RAs to vulnerable populations such as preterm infants .
Comparative Safety with Other Acid Suppressants
When compared to PPIs, H2RAs do not show a higher risk of dementia, and overall, neither class appears to be independently associated with dementia risk in patients treated for Helicobacter pylori infection . In cardiac surgery patients, H2RAs and PPIs had similar safety profiles regarding mortality, gastrointestinal bleeding, and infection risks .
Special Populations and Considerations
In patients with COVID-19, preventive use of acid blockers (including H2RAs) for gastrointestinal ulcers was found to be not sufficiently effective and potentially unsafe, suggesting a need for further research in this area .
Conclusion
H2 receptor blockers remain effective and generally safe for the treatment of acid-related gastrointestinal disorders, with a well-established role in clinical practice. However, clinicians should be aware of specific risks, particularly in vulnerable populations such as VLBW infants and possibly in patients with COVID-19. While H2RAs are comparable to PPIs in many settings, careful patient selection and adherence to recommended dosing and duration are important to minimize potential adverse effects Meng2022Belovol2019Romaine2016+4 MORE.
Sources and full results
Most relevant research papers on this topic
Haemodynamic effects of H2‐receptor antagonists
H2-receptor antagonists are effective in treating peptic ulcer disease, Zollinger-Ellison syndrome, and other conditions, but their use is associated with a small but significant increase in cardiovascular adverse reactions.
Clinical pharmacology of antisecretory drugs. Focus on H2-histamine receptor blockers
H2-histamine receptor blockers are effective short-term treatments for various acid-dependent diseases, but are gradually being replaced by more powerful antisecretory drugs like proton pump inhibitors.
Efficacy and safety of proton pump inhibitors versus histamine-2 receptor blockers in the cardiac surgical population: insights from the PEPTIC trial.
No differences in effectiveness or safety were observed between proton pump inhibitors and histamine-2 receptor blockers for stress ulcer prophylaxis in cardiac surgery patients enrolled in the PEPTIC trial in Canada.
DOI